Original Article
Short-term safety evaluation of intraperitoneal chemotherapy with Raltitrexed for colorectal cancer
Jianan Chen, Zheng Wang, Along Zhang, Zheng Liu, Haiyu Shen, Zhijie Wang, Fuqiang Zhao, Shiwen Mei, Qian Liu
Published 2019-06-25
Cite as Chin J Colorec Dis (Electronic Edition), 2019, 08(3): 241-245. DOI: 10.3877/cma.j.issn.2095-3224.2019.03.006
Abstract
ObjectiveTo evaluate of the recent safety and feasibility of intraoperative intraperitoneal chemotherapy with Raltitrexed for colorectal cancer patients.
MethodsThe clinical data of colorectal cancer patients undergoing surgery from the National Cancer Center from July 2017 to October 2018 were retrospectively analyzed. 80 colorectal cancer patients who underwent radical surgery were divided into two groups. The Raltitrexed group (40 patients), who received intraoperative intraperitoneal perfusion chemotherapy with Raltitrexed and the control group (40 patients), who did not receive intraoperative intraperitoneal perfusion chemotherapy. Analysis of the recent safety differences between the two groups in terms of postoperative complications, liver and kidney function, hematological toxicity, and time of gastrointestinal function recovery.
ResultsThere was no significant differences in the incidence of postoperative complications, liver and kidney function, blood toxicity and recovery time of gastrointestinal function between the two groups (all P>0.05).
ConclusionsIntraoperative perfusion with Raltitrexed for patients with colorectal cancer has good safety and tolerability, and does not increase postoperative complications.
Key words:
Colorectal neoplasms; Surgery; Raltitrexed; Intraperitoneal perfusion chemotherapy; Safety
Contributor Information
Jianan Chen
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Zheng Wang
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Along Zhang
Department of General Surgery, First People′s Hospital, Shizuishan City, Ningxia Hui Autonomous Region, Shizuishan 753200, China
Zheng Liu
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Haiyu Shen
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Zhijie Wang
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Fuqiang Zhao
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Shiwen Mei
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
Qian Liu
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100021, China
